Page last updated: 2024-11-11

n(6)-cyclohexyladenosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N(6)-cyclohexyladenosine: structure given in first source; receptors, purinergic P1 agonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9841284
CHEMBL ID45891
SCHEMBL ID145856
MeSH IDM0089359

Synonyms (46)

Synonym
gtpl423
(2r,3r,4s,5r)-2-[6-(cyclohexylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
PDSP1_001023
PDSP2_000660
PDSP2_001009
EU-0100331
n6-cyclohexyladenosine
PDSP1_000670
PDSP1_001025
PDSP2_001007
LOPAC0_000331
NCGC00093771-03
NCGC00093771-02
NCGC00093771-01
C 9901
NCGC00093771-04
CHEMBL45891 ,
36396-99-3
n6-cyclohexylado (cha)
bdbm50009552
2-[6-amino-2-(2-morpholin-4-yl-ethylamino)-purin-9-yl]-5-hydroxymethyl-tetrahydro-furan-3,4-diol
HMS3261C03
n(6)-cyclohexyladenosine
CCG-204426
AKOS016009588
LP00331
SCHEMBL145856
n6 -cyclohexyladenosine
SZBULDQSDUXAPJ-XNIJJKJLSA-N
(2r,3r,4s,5r)-2-(6-(cyclohexylamino)-9h-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
CS-5050
tox21_500331
NCGC00261016-01
n6-cyclohexyl[3h]adenosine
n-cyclohexyladenosine
HY-18939
AC-27401
sr-01000075797
SR-01000075797-1
n-6-cyclohexyladenosine
Q27087820
SDCCGSBI-0050319.P002
NCGC00093771-06
E78490
BS-49179
A855738

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"It is proposed the data obtained by these in vitro experiments can be used to investigate the in vivo pharmacodynamic of A, full and partial agonists."( Thermodynamic in vitro studies as a method to investigate the pharmacodynamic behavior of adenosine A1 receptor ligands.
Andrea Borea, P; Dalpiaz, A; IJzerman, AP; Pavan, B; Scatturin, A; Varani, K, 1999
)
0.3

Dosage Studied

ExcerptRelevanceReference
" An unexpected finding was that R-PIA, 2-CA and CHA all induced contractions at concentrations lower than were required for relaxation, giving a biphasic dose-response curve."( The coexistence of adenosine A1 and A2 receptors in guinea-pig aorta.
Shaw, JS; Stoggall, SM, 1990
)
0.28
" From dose-response curves it was found that APEC (ED50 16 micrograms/kg) is more potent than CHA (ED50 60 micrograms/kg) and less potent than NECA (ED50 2 micrograms/kg)."( Characterization of the locomotor depression produced by an A2-selective adenosine agonist.
Daly, JW; Jacobson, KA; Nikodijević, O, 1990
)
0.28
" Adenosine also increased the histamine-induced contraction causing a leftward shift of the histamine dose-response curves, an effect that was abolished in the presence of atropine."( Adenosine potentiates neurally- and histamine-induced contraction of canine airway smooth muscle.
Katayama, M; Kobayashi, K; Sakai, N; Takizawa, T; Tamaoki, J, 1989
)
0.28
" Maximal inhibition was observed at a concentration of 10 nM PIA, and the ED50 of the dose-response curve was 1 nM."( Adenosine inhibition of the hormonal response in the Sertoli cell is reversed by pertussis toxin.
Conti, M; DeManno, DA; Martin, MW; Monaco, L, 1988
)
0.27
" N6-cyclohexyladenosine (CHA) had a biphasic effect on renin secretion: submicromolar concentrations inhibited concentration-dependently, and there was an inflection in the dose-response curve near 1 microM CHA such that higher concentrations produced a concentration-dependent relative stimulation, which became an absolute stimulation (i."( XAC, a functionalized congener of 1,3-dialkylxanthine, antagonizes A1 adenosine receptor-mediated inhibition of renin secretion in vitro.
Churchill, MC; Churchill, PC; Jacobson, KA, 1987
)
0.27
" The study also investigated the effects of a known adenosine antagonist, namely, the xanthine derivative 8-phenyltheophylline, which at concentrations having no intrinsic effect (10(-8) and 10(-7) M) produced a significant shift to the right only for the NECA dose-response curve."( Effects of adenosine and its analogues on porcine basilar arteries: are only A2 receptors involved?
Harper, AM; McBean, DE; Rudolphi, KA, 1988
)
0.27
" Caffeine stimulated locomotor activity of both strains, but the dose-response relationship and time course of drug action differed according to strain."( Effects of caffeine and L-phenylisopropyladenosine on locomotor activity of mice.
Buckholtz, NS; Middaugh, LD, 1987
)
0.27
" Further studies indicated that CHA-stimulated Ieq was independent of cAMP generation because CHA did not induce an increase in cAMP accumulation parallel to the increase in Ieq in a dose-response analysis, and the adenylate cyclase inhibitor 2',5' dideoxy-adenosine (DDA) did not affect the CHA-induced increase in Ieq."( Adenosine stimulation of Na+ transport is mediated by an A1 receptor and a [Ca2+]i-dependent mechanism.
Gasalla-Herraiz, J; Hayslett, JP; Isales, C; Kalghatgi, L; Macala, LJ; Smallwood, JI, 1995
)
0.29
" Dose-response curves were constructed for the ability of theophylline to produce tonic seizures in animals pre-treated with vehicle or several adenosine A1 receptor agonists."( Adenosine receptors are not involved in theophylline-induced seizures.
Hornfeldt, CS; Larson, AA, 1994
)
0.29
" Theophylline, an antagonist of P1 adenosine receptor, completely reversed the effect of adenosine on the furosemide-sensitive ATPase activity in a dose-response manner."( Effect of adenosine on the ouabain-insensitive Na+-ATPase activity from basolateral membrane of the proximal tubule.
Caruso-Neves, C; Chagas, C; Francisco-Pedro, LG; Lopes, AG; Souza, LP, 1997
)
0.3
" This dual mechanism of action is consistent with analysis of CHA dose-response curve, which indicates that the reduction in IOP induced this agonist's results from multiple mechanisms of action."( Intraocular pressure responses to the adenosine agonist cyclohexyladenosine: evidence for a dual mechanism of action.
Crosson, CE, 2001
)
0.31
" These indicate that HPMA at this dosage (IC50 dosage) preferentially acted on presynapse (may be the A1 receptor) to attenuate the release of neurotransmitters."( [The A1- and non A1-effects of N6-(5-hydroxy-2-pyridyl)-methyl-adenosine on rat vas deferens].
Huang, J; Xiong, J, 1998
)
0.3
" PTX pretreatment did not affect the constriction response to KCl, whereas the angiotensin II dose-response relationship was shifted rightward."( Adenosine induces vasoconstriction through Gi-dependent activation of phospholipase C in isolated perfused afferent arterioles of mice.
Briggs, J; Castrop, H; Hansen, PB; Schnermann, J, 2003
)
0.32
" Pretreatment with 1 micromol/L CHA for 24 h caused a right shift of the dose-response curve of DPDPE-mediated inhibition of cAMP accumulation, with a significant increase in EC(50) but no change in E(max)."( Adenosine A(1) receptor agonist N(6)-cyclohexyl-adenosine induced phosphorylation of delta opioid receptor and desensitization of its signaling.
Chen, J; Cheng, Y; Chi, ZQ; Liu, JG; Sun, JF; Tao, YM; Wang, YH; Xu, XJ, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (17)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency39.81070.004023.8416100.0000AID485290
dopamine D1 receptorHomo sapiens (human)Potency0.05800.00521.30228.1995AID624455
thioredoxin reductaseRattus norvegicus (Norway rat)Potency2.99350.100020.879379.4328AID488773; AID588453
ATAD5 protein, partialHomo sapiens (human)Potency2.05880.004110.890331.5287AID493107
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency8.04970.001530.607315,848.9004AID1224821; AID1224823
arylsulfatase AHomo sapiens (human)Potency0.03791.069113.955137.9330AID720538
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency75.686323.934123.934123.9341AID1967
survival motor neuron protein isoform dHomo sapiens (human)Potency3.54810.125912.234435.4813AID1458
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.75690.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A1Rattus norvegicus (Norway rat)IC50 (µMol)0.00240.00020.552110.0000AID30337; AID31403; AID31410; AID34007
Adenosine receptor A1Rattus norvegicus (Norway rat)Ki0.00410.00011.20929.9700AID196738; AID31850; AID32012; AID32177; AID32203; AID32204; AID32324; AID32503
Adenosine receptor A3Rattus norvegicus (Norway rat)IC50 (µMol)0.00240.00070.03740.0957AID34007
Adenosine receptor A3Rattus norvegicus (Norway rat)Ki0.00700.00030.91969.0000AID196738
Adenosine receptor A2bRattus norvegicus (Norway rat)IC50 (µMol)0.58800.00240.68169.0000AID30819; AID33405; AID33406; AID34007
Adenosine receptor A2bRattus norvegicus (Norway rat)Ki6.26860.00061.353610.0000AID196738; AID33590; AID33727; AID33733
Adenosine receptor A2aRattus norvegicus (Norway rat)IC50 (µMol)0.58800.00120.48289.0000AID30819; AID33405; AID33406; AID34007
Adenosine receptor A2aRattus norvegicus (Norway rat)Ki5.32380.00021.494010.0000AID196738; AID32863; AID33590; AID33727; AID33733
Adenosine receptor A1Gallus gallus (chicken)IC50 (µMol)0.00250.00250.00800.0170AID31835
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A1Rattus norvegicus (Norway rat)Kd0.00130.00130.56301.9498AID1280094
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A2aHomo sapiens (human)Affinity constant30.00000.20006.028610.0000AID33909
Adenosine receptor A2bHomo sapiens (human)Affinity constant30.00000.20006.028610.0000AID33909
Adenosine receptor A2bRattus norvegicus (Norway rat)Ratio0.51400.00330.82929.6000AID33746
Adenosine receptor A1Homo sapiens (human)Affinity constant0.00300.00301.069110.0000AID30353
Adenosine receptor A2aRattus norvegicus (Norway rat)Ratio0.51400.00330.82309.6000AID33746
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (101)

Processvia Protein(s)Taxonomy
synaptic transmission, dopaminergicAdenosine receptor A2aHomo sapiens (human)
response to amphetamineAdenosine receptor A2aHomo sapiens (human)
regulation of DNA-templated transcriptionAdenosine receptor A2aHomo sapiens (human)
phagocytosisAdenosine receptor A2aHomo sapiens (human)
apoptotic processAdenosine receptor A2aHomo sapiens (human)
inflammatory responseAdenosine receptor A2aHomo sapiens (human)
cellular defense responseAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
cell-cell signalingAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, cholinergicAdenosine receptor A2aHomo sapiens (human)
central nervous system developmentAdenosine receptor A2aHomo sapiens (human)
blood coagulationAdenosine receptor A2aHomo sapiens (human)
sensory perceptionAdenosine receptor A2aHomo sapiens (human)
locomotory behaviorAdenosine receptor A2aHomo sapiens (human)
blood circulationAdenosine receptor A2aHomo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A2aHomo sapiens (human)
response to xenobiotic stimulusAdenosine receptor A2aHomo sapiens (human)
response to inorganic substanceAdenosine receptor A2aHomo sapiens (human)
positive regulation of glutamate secretionAdenosine receptor A2aHomo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmissionAdenosine receptor A2aHomo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A2aHomo sapiens (human)
response to purine-containing compoundAdenosine receptor A2aHomo sapiens (human)
response to caffeineAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
positive regulation of urine volumeAdenosine receptor A2aHomo sapiens (human)
vasodilationAdenosine receptor A2aHomo sapiens (human)
eating behaviorAdenosine receptor A2aHomo sapiens (human)
negative regulation of vascular permeabilityAdenosine receptor A2aHomo sapiens (human)
negative regulation of neuron apoptotic processAdenosine receptor A2aHomo sapiens (human)
positive regulation of circadian sleep/wake cycle, sleepAdenosine receptor A2aHomo sapiens (human)
negative regulation of alpha-beta T cell activationAdenosine receptor A2aHomo sapiens (human)
astrocyte activationAdenosine receptor A2aHomo sapiens (human)
neuron projection morphogenesisAdenosine receptor A2aHomo sapiens (human)
positive regulation of protein secretionAdenosine receptor A2aHomo sapiens (human)
negative regulation of inflammatory responseAdenosine receptor A2aHomo sapiens (human)
regulation of mitochondrial membrane potentialAdenosine receptor A2aHomo sapiens (human)
membrane depolarizationAdenosine receptor A2aHomo sapiens (human)
regulation of calcium ion transportAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
excitatory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
inhibitory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
prepulse inhibitionAdenosine receptor A2aHomo sapiens (human)
apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A2aHomo sapiens (human)
positive regulation of long-term synaptic potentiationAdenosine receptor A2aHomo sapiens (human)
positive regulation of apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
positive regulation of chronic inflammatory response to non-antigenic stimulusAdenosine receptor A2bHomo sapiens (human)
G protein-coupled receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
activation of adenylate cyclase activityAdenosine receptor A2bHomo sapiens (human)
positive regulation of vascular endothelial growth factor productionAdenosine receptor A2bHomo sapiens (human)
positive regulation of cGMP-mediated signalingAdenosine receptor A2bHomo sapiens (human)
cGMP-mediated signalingAdenosine receptor A2bHomo sapiens (human)
positive regulation of chemokine productionAdenosine receptor A2bHomo sapiens (human)
positive regulation of interleukin-6 productionAdenosine receptor A2bHomo sapiens (human)
mast cell degranulationAdenosine receptor A2bHomo sapiens (human)
positive regulation of mast cell degranulationAdenosine receptor A2bHomo sapiens (human)
relaxation of vascular associated smooth muscleAdenosine receptor A2bHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A2bHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2bHomo sapiens (human)
vasodilationAdenosine receptor A2bHomo sapiens (human)
temperature homeostasisAdenosine receptor A1Homo sapiens (human)
response to hypoxiaAdenosine receptor A1Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
regulation of respiratory gaseous exchange by nervous system processAdenosine receptor A1Homo sapiens (human)
negative regulation of acute inflammatory responseAdenosine receptor A1Homo sapiens (human)
negative regulation of leukocyte migrationAdenosine receptor A1Homo sapiens (human)
positive regulation of peptide secretionAdenosine receptor A1Homo sapiens (human)
positive regulation of systemic arterial blood pressureAdenosine receptor A1Homo sapiens (human)
negative regulation of systemic arterial blood pressureAdenosine receptor A1Homo sapiens (human)
regulation of glomerular filtrationAdenosine receptor A1Homo sapiens (human)
protein targeting to membraneAdenosine receptor A1Homo sapiens (human)
phagocytosisAdenosine receptor A1Homo sapiens (human)
inflammatory responseAdenosine receptor A1Homo sapiens (human)
signal transductionAdenosine receptor A1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
cell-cell signalingAdenosine receptor A1Homo sapiens (human)
nervous system developmentAdenosine receptor A1Homo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A1Homo sapiens (human)
response to inorganic substanceAdenosine receptor A1Homo sapiens (human)
negative regulation of glutamate secretionAdenosine receptor A1Homo sapiens (human)
response to purine-containing compoundAdenosine receptor A1Homo sapiens (human)
lipid catabolic processAdenosine receptor A1Homo sapiens (human)
negative regulation of synaptic transmission, GABAergicAdenosine receptor A1Homo sapiens (human)
positive regulation of nucleoside transportAdenosine receptor A1Homo sapiens (human)
negative regulation of neurotrophin productionAdenosine receptor A1Homo sapiens (human)
positive regulation of protein dephosphorylationAdenosine receptor A1Homo sapiens (human)
vasodilationAdenosine receptor A1Homo sapiens (human)
negative regulation of circadian sleep/wake cycle, non-REM sleepAdenosine receptor A1Homo sapiens (human)
negative regulation of apoptotic processAdenosine receptor A1Homo sapiens (human)
positive regulation of potassium ion transportAdenosine receptor A1Homo sapiens (human)
positive regulation of MAPK cascadeAdenosine receptor A1Homo sapiens (human)
negative regulation of hormone secretionAdenosine receptor A1Homo sapiens (human)
cognitionAdenosine receptor A1Homo sapiens (human)
leukocyte migrationAdenosine receptor A1Homo sapiens (human)
detection of temperature stimulus involved in sensory perception of painAdenosine receptor A1Homo sapiens (human)
negative regulation of lipid catabolic processAdenosine receptor A1Homo sapiens (human)
positive regulation of lipid catabolic processAdenosine receptor A1Homo sapiens (human)
regulation of sensory perception of painAdenosine receptor A1Homo sapiens (human)
negative regulation of synaptic transmission, glutamatergicAdenosine receptor A1Homo sapiens (human)
fatty acid homeostasisAdenosine receptor A1Homo sapiens (human)
excitatory postsynaptic potentialAdenosine receptor A1Homo sapiens (human)
long-term synaptic depressionAdenosine receptor A1Homo sapiens (human)
mucus secretionAdenosine receptor A1Homo sapiens (human)
negative regulation of mucus secretionAdenosine receptor A1Homo sapiens (human)
triglyceride homeostasisAdenosine receptor A1Homo sapiens (human)
regulation of cardiac muscle cell contractionAdenosine receptor A1Homo sapiens (human)
apoptotic signaling pathwayAdenosine receptor A1Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentrationAdenosine receptor A1Homo sapiens (human)
negative regulation of long-term synaptic potentiationAdenosine receptor A1Homo sapiens (human)
negative regulation of long-term synaptic depressionAdenosine receptor A1Homo sapiens (human)
G protein-coupled receptor signaling pathwayAdenosine receptor A1Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A1Gallus gallus (chicken)
G protein-coupled receptor signaling pathwayAdenosine receptor A1Gallus gallus (chicken)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (16)

Processvia Protein(s)Taxonomy
G protein-coupled adenosine receptor activityAdenosine receptor A2aHomo sapiens (human)
protein bindingAdenosine receptor A2aHomo sapiens (human)
calmodulin bindingAdenosine receptor A2aHomo sapiens (human)
lipid bindingAdenosine receptor A2aHomo sapiens (human)
enzyme bindingAdenosine receptor A2aHomo sapiens (human)
type 5 metabotropic glutamate receptor bindingAdenosine receptor A2aHomo sapiens (human)
identical protein bindingAdenosine receptor A2aHomo sapiens (human)
protein-containing complex bindingAdenosine receptor A2aHomo sapiens (human)
alpha-actinin bindingAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2bHomo sapiens (human)
protein bindingAdenosine receptor A2bHomo sapiens (human)
G protein-coupled receptor activityAdenosine receptor A2bHomo sapiens (human)
G protein-coupled receptor bindingAdenosine receptor A1Homo sapiens (human)
purine nucleoside bindingAdenosine receptor A1Homo sapiens (human)
protein bindingAdenosine receptor A1Homo sapiens (human)
heat shock protein bindingAdenosine receptor A1Homo sapiens (human)
G-protein beta/gamma-subunit complex bindingAdenosine receptor A1Homo sapiens (human)
heterotrimeric G-protein bindingAdenosine receptor A1Homo sapiens (human)
protein heterodimerization activityAdenosine receptor A1Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A1Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aRattus norvegicus (Norway rat)
G protein-coupled adenosine receptor activityAdenosine receptor A1Gallus gallus (chicken)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
plasma membraneAdenosine receptor A2aHomo sapiens (human)
intermediate filamentAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
membraneAdenosine receptor A2aHomo sapiens (human)
dendriteAdenosine receptor A2aHomo sapiens (human)
axolemmaAdenosine receptor A2aHomo sapiens (human)
asymmetric synapseAdenosine receptor A2aHomo sapiens (human)
presynaptic membraneAdenosine receptor A2aHomo sapiens (human)
neuronal cell bodyAdenosine receptor A2aHomo sapiens (human)
postsynaptic membraneAdenosine receptor A2aHomo sapiens (human)
presynaptic active zoneAdenosine receptor A2aHomo sapiens (human)
glutamatergic synapseAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A2bHomo sapiens (human)
Schaffer collateral - CA1 synapseAdenosine receptor A2bHomo sapiens (human)
presynapseAdenosine receptor A2bHomo sapiens (human)
glutamatergic synapseAdenosine receptor A2bHomo sapiens (human)
plasma membraneAdenosine receptor A2bHomo sapiens (human)
plasma membraneAdenosine receptor A1Homo sapiens (human)
plasma membraneAdenosine receptor A1Homo sapiens (human)
basolateral plasma membraneAdenosine receptor A1Homo sapiens (human)
axolemmaAdenosine receptor A1Homo sapiens (human)
asymmetric synapseAdenosine receptor A1Homo sapiens (human)
presynaptic membraneAdenosine receptor A1Homo sapiens (human)
neuronal cell bodyAdenosine receptor A1Homo sapiens (human)
terminal boutonAdenosine receptor A1Homo sapiens (human)
dendritic spineAdenosine receptor A1Homo sapiens (human)
calyx of HeldAdenosine receptor A1Homo sapiens (human)
postsynaptic membraneAdenosine receptor A1Homo sapiens (human)
presynaptic active zoneAdenosine receptor A1Homo sapiens (human)
synapseAdenosine receptor A1Homo sapiens (human)
dendriteAdenosine receptor A1Homo sapiens (human)
Golgi membraneAdenosine receptor A2aRattus norvegicus (Norway rat)
plasma membraneAdenosine receptor A1Gallus gallus (chicken)
synapseAdenosine receptor A1Gallus gallus (chicken)
dendriteAdenosine receptor A1Gallus gallus (chicken)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (101)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID25507HPLC capacity factor (k')1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Dog coronary artery adenosine receptor: structure of the N6-alkyl subregion.
AID186236Maximal % inhibition of adenylyl cyclase activity in rat cortical membranes at a concentration of 10 uM.1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies.
AID194217Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.
AID235521Selectivity, ratio of affinity towards adenosine A3 to A12000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
A novel class of highly potent and selective A1 adenosine antagonists: structure-affinity profile of a series of 1,8-naphthyridine derivatives.
AID180662The compound was tested for the concentration to inhibit 50% of Adenylyl cyclase activity in rat cortical membranes.1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies.
AID33590Displacement of [3H]-NECA from adenosine A2 receptor of rat striatal membrane1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
N6-cycloalkyladenosines. Potent, A1-selective adenosine agonists.
AID33909Affinity constant for A2 receptor control of adenylate cyclase in adipocytes, heart and brain cells1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Adenosine receptors: targets for future drugs.
AID33948Selectivity ratio of Ki of the adenosine A2a receptor and Ki of adenosine A1 receptor2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
N-cycloalkyl derivatives of adenosine and 1-deazaadenosine as agonists and partial agonists of the A(1) adenosine receptor.
AID1430041Antiviral activity against TEBV Absettarov infected in PEK cells assessed as inhibition of viral reproduction at 50 uM preincubated with virus for 1 hr followed by addition to PEK cells measured after 1 hr by gentian violet staining based plaque reduction2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
New tools in nucleoside toolbox of tick-borne encephalitis virus reproduction inhibitors.
AID340154Antitumor activity against human CaCo2 cells after 48 hrs by MTS assay2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Ribose-modified purine nucleosides as ribonucleotide reductase inhibitors. Synthesis, antitumor activity, and molecular modeling of N6-substituted 3'-C-methyladenosine derivatives.
AID32177Binding affinity against adenosine A1 receptor using [3H]-CHA or [3H]PIA as radioligand1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.
AID330858Agonist activity at human adenosine A2B receptor expressed in CHO cells assessed as stimulation of adenylate cyclase2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Probing distal regions of the A2B adenosine receptor by quantitative structure-activity relationship modeling of known and novel agonists.
AID235175Relative affinities for adenosine A2 and A1 receptors1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
N6-phenyladenosines: pronounced effect of phenyl substituents on affinity for A2 adenosine receptors.
AID235522Selectivity, ratio of affinity towards adenosine A3 to A2A2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
A novel class of highly potent and selective A1 adenosine antagonists: structure-affinity profile of a series of 1,8-naphthyridine derivatives.
AID33591Binding of Adenosine A2 receptor in whole rat brain membrane using [3H]CHA as a Radioligand1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
A novel synthesis of xanthines: support for a new binding mode for xanthines with respect to adenosine at adenosine receptors.
AID33746Binding affinity against adenosine A2 receptor using [3H]- NECA as radioligand1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.
AID195546Antagonist binding of N6-cyclohexyl-[3H]-adenosine in rat brain1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Adenosine receptors: targets for future drugs.
AID32204Binding affinity for Adenosine A1 receptor in corpora striata of rats using [3H]NECA1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.
AID1430044Cytotoxicity against PEK cells after 7 days2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
New tools in nucleoside toolbox of tick-borne encephalitis virus reproduction inhibitors.
AID186235Inhibitory activity against Adenylyl cyclase in rat cortical membranes in the presence of 2''-Me-CPA at concentration 50 nM1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies.
AID32503Inhibition of binding of [3H]N6-cyclohexyladenosine to adenosine A1 receptor of rat whole brain membranes.1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
C2,N6-disubstituted adenosines: synthesis and structure-activity relationships.
AID33733Inhibition of binding of [3H]NECA to adenosine A2 receptor of rat striatal membranes.1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
C2,N6-disubstituted adenosines: synthesis and structure-activity relationships.
AID1430042Antiviral activity against TEBV Absettarov infected in PEK cells assessed as inhibition of viral reproduction preincubated with virus for 1 hr followed by addition to PEK cells measured after 1 hr by gentian violet staining based plaque reduction assay2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
New tools in nucleoside toolbox of tick-borne encephalitis virus reproduction inhibitors.
AID340153Antitumor activity against human K562 cells after 48 hrs by MTS assay2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Ribose-modified purine nucleosides as ribonucleotide reductase inhibitors. Synthesis, antitumor activity, and molecular modeling of N6-substituted 3'-C-methyladenosine derivatives.
AID30819Displacement of [3H]-NECA from adenosine A2 receptor of rat striatal membrane1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
N6-phenyladenosines: pronounced effect of phenyl substituents on affinity for A2 adenosine receptors.
AID31403Binding affinity towards the adenosine A1 receptor in cerebral cortices of Sprague-Dawley male rats using [3H]CHA as radioligand.1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.
AID32863Binding affinity for adenosine A2A receptor was determined by displacement of [3H]-DPCPX from rat striatal membranes.2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
N-cycloalkyl derivatives of adenosine and 1-deazaadenosine as agonists and partial agonists of the A(1) adenosine receptor.
AID180136Inhibitory activity against Adenylyl cyclase in rat cortical membranes in the presence of 2''-Me-CCPA at concentration 30 nM1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies.
AID445467Displacement of [3H]adenine from adenine 1 receptor in rat brain cortical membrane by liquid scintillation counting2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Structure-activity relationships of adenine and deazaadenine derivatives as ligands for adenine receptors, a new purinergic receptor family.
AID78489Antagonist binding of N6-cyclohexyl-[3H]-adenosine to guinea pig brain1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Adenosine receptors: targets for future drugs.
AID186234Inhibitory activity against Adenylyl cyclase in rat cortical membranes in the presence of 2''-Me-CCPA at concentration 30 nM1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies.
AID34160Inhibition of Adenylate Cyclase in Rat adipocytes1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
A novel synthesis of xanthines: support for a new binding mode for xanthines with respect to adenosine at adenosine receptors.
AID30353Affinity constant for inhibition of A1 receptor control of adenylate cyclase in adipocytes, heart and brain cells1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Adenosine receptors: targets for future drugs.
AID33917Ability to displace the specific binding of [3H]-CGS- to adenosine A2A receptor form bovine brain striatal membranes2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
A novel class of highly potent and selective A1 adenosine antagonists: structure-affinity profile of a series of 1,8-naphthyridine derivatives.
AID330859Agonist activity human adenosine A2B receptor expressed in CHO cells assessed as stimulation of adenylate cyclase relative to NECA2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
Probing distal regions of the A2B adenosine receptor by quantitative structure-activity relationship modeling of known and novel agonists.
AID33405Concentration required for 50% inhibition of [3H]NECA binding on rat brain adenosine A2 receptor1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.
AID340155Antitumor activity against human HT29 cells after 48 hrs by MTS assay2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Ribose-modified purine nucleosides as ribonucleotide reductase inhibitors. Synthesis, antitumor activity, and molecular modeling of N6-substituted 3'-C-methyladenosine derivatives.
AID17397425% reduction in blood pressure in the rat.1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.
AID34117Ability to displace the specific binding of [3H](R)-PIA to adenosine A3 receptor from rat testis membranes2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
A novel class of highly potent and selective A1 adenosine antagonists: structure-affinity profile of a series of 1,8-naphthyridine derivatives.
AID33752Ratio of A2 to A1.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.
AID31976Ability to displace the specific binding of [3H]CHA to adenosine A1 receptor from bovine brain cortical membranes2000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
A novel class of highly potent and selective A1 adenosine antagonists: structure-affinity profile of a series of 1,8-naphthyridine derivatives.
AID34007Displacement of [3H]CHA from rat brain adenosine receptor1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
C4-substituted 1-beta-D-ribofuranosylpyrazolo[3,4-d]pyrimidines as adenosine agonist analogues.
AID1430043Cytotoxicity against PEK cells after 24 hrs2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
New tools in nucleoside toolbox of tick-borne encephalitis virus reproduction inhibitors.
AID31410Concentration required for 50% inhibition of [3H]-CHA binding on rat brain adenosine A1 receptor1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.
AID32206Displacement of [3H]CHA from adenosine A1 receptor of rat whole brain1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
N6-cycloalkyladenosines. Potent, A1-selective adenosine agonists.
AID196931Antagonist binding of N6-cyclohexyl-[3H]-adenosine to rat testes1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Adenosine receptors: targets for future drugs.
AID33406Evaluated for the binding affinity towards the Adenosine A2 receptor in corpora striata of rats using [3H]NECA as radioligand.1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.
AID34158Inhibition of adenyl cyclase via P site in adipocytes; Inactive1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Adenosine receptors: targets for future drugs.
AID228918Molar potency ratio was evaluated1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Dog coronary artery adenosine receptor: structure of the N6-alkyl subregion.
AID33727Binding affinity for adenosine A2 receptor in corpora striata of rats using [3H]NECA1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.
AID28933Lipophilicity value was evaluated1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
N6-cycloalkyladenosines. Potent, A1-selective adenosine agonists.
AID232472Selectivity ratio for A1 receptor to that of A2 receptor in vitro in rat tissues1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
C2,N6-disubstituted adenosines: synthesis and structure-activity relationships.
AID31835Displacement of [125I]ABA from adenosine A1 receptor of chick cerebellar membrane1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
N6-phenyladenosines: pronounced effect of phenyl substituents on affinity for A2 adenosine receptors.
AID203468Serum albumin binding1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Dog coronary artery adenosine receptor: structure of the N6-alkyl subregion.
AID180135Inhibitory activity against Adenylyl cyclase in rat cortical membranes in the presence of 2''-IB-Ado at concentration 30 nM1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies.
AID180137Inhibitory activity against Adenylyl cyclase in rat cortical membranes in the presence of 2''-Me-CPA at concentration 50 nM1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies.
AID32639Ratio of IC50 values for A1 receptor binding to that of A2 receptor1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines.
AID179751In vitro inhibition of synaptic potential in the hippocampal formation (synaptic responses (fEPSPs) recorded in the CAI region of in vivo hippocampal slices in rat brain)1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Synthesis and biological activity of N6-(p-sulfophenyl)alkyl and N6-sulfoalkyl derivatives of adenosine: water-soluble and peripherally selective adenosine agonists.
AID235520Selectivity, ratio of affinity towards adenosine A2A to A12000Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15
A novel class of highly potent and selective A1 adenosine antagonists: structure-affinity profile of a series of 1,8-naphthyridine derivatives.
AID30337Evaluated for binding affinity against Adenosine A1 receptor1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
A steric and electrostatic comparison of three models for the agonist/antagonist binding site on the adenosine A1 receptor.
AID42825Antagonist binding of N6-cyclohexyl-[3H]-adenosine to bovine brain1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Adenosine receptors: targets for future drugs.
AID196738Antagonist binding of L-N6-phenyl-isopropyl)-[3H]adenosine to rat fat1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Adenosine receptors: targets for future drugs.
AID1280094Displacement of [3H] CGS 21680 from rat hippocampus adenosine A1 receptor2016Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3
Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.
AID32324Inhibition of [3H]-CHA binding to rat brain membrane Adenosine A1 receptor1990Journal of medicinal chemistry, Dec, Volume: 33, Issue:12
A novel synthesis of xanthines: support for a new binding mode for xanthines with respect to adenosine at adenosine receptors.
AID203472Serum albumin binding, dissociation constant1985Journal of medicinal chemistry, Nov, Volume: 28, Issue:11
Dog coronary artery adenosine receptor: structure of the N6-alkyl subregion.
AID32203Binding affinity for Adenosine A1 receptor in cerebral cortices of Sprague-Dawley male rats using [3H]CHA1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.
AID340156Antitumor activity against human MCF7 cells after 48 hrs by MTS assay2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Ribose-modified purine nucleosides as ribonucleotide reductase inhibitors. Synthesis, antitumor activity, and molecular modeling of N6-substituted 3'-C-methyladenosine derivatives.
AID32012Binding affinity for adenosine A1 receptor was assayed by displacement of [3H]DPCPX from rat cortical membranes.2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
N-cycloalkyl derivatives of adenosine and 1-deazaadenosine as agonists and partial agonists of the A(1) adenosine receptor.
AID229446Relative binding to A2 and A1 receptors (ratio of Ki)1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
N6-cycloalkyladenosines. Potent, A1-selective adenosine agonists.
AID186233Inhibitory activity against Adenylyl cyclase in rat cortical membranes in the presence of 2''-IB-Ado at concentration 30 nM1998Journal of medicinal chemistry, May-07, Volume: 41, Issue:10
2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies.
AID155531Inhibition of Trypanosoma brucei phosphoglycerate kinase (PGK); inactive at 4 mM2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Adenosine analogues as inhibitors of Trypanosoma brucei phosphoglycerate kinase: elucidation of a novel binding mode for a 2-amino-N(6)-substituted adenosine.
AID31850Inhibition of [3H]PIA binding to rat cortical adenosine A1 receptor1992Journal of medicinal chemistry, Oct-30, Volume: 35, Issue:22
Synthesis and biological activity of N6-(p-sulfophenyl)alkyl and N6-sulfoalkyl derivatives of adenosine: water-soluble and peripherally selective adenosine agonists.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1345630Rat A1 receptor (Adenosine receptors)1993Pharmacology, , Volume: 46, Issue:2
Structure-activity relationships for 2-substituted adenosines at A1 and A2 adenosine receptors.
AID1345822Human A3 receptor (Adenosine receptors)1996Journal of immunology (Baltimore, Md. : 1950), May-01, Volume: 156, Issue:9
Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors.
AID1345831Rat A3 receptor (Adenosine receptors)1994Molecular pharmacology, Jun, Volume: 45, Issue:6
A binding site model and structure-activity relationships for the rat A3 adenosine receptor.
AID1345721Human A2B receptor (Adenosine receptors)1980Canadian journal of physiology and pharmacology, Jun, Volume: 58, Issue:6
Adenosine receptor activation in human fibroblasts: nucleoside agonists and antagonists.
AID1345618Human A2A receptor (Adenosine receptors)1997British journal of pharmacology, Jun, Volume: 121, Issue:3
Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261.
AID1345618Human A2A receptor (Adenosine receptors)1999Biochemical pharmacology, Jan-01, Volume: 57, Issue:1
Differences in the order of potency for agonists but not antagonists at human and rat adenosine A2A receptors.
AID1345690Rat A2A receptor (Adenosine receptors)1993Pharmacology, , Volume: 46, Issue:2
Structure-activity relationships for 2-substituted adenosines at A1 and A2 adenosine receptors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (529)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990166 (31.38)18.7374
1990's247 (46.69)18.2507
2000's76 (14.37)29.6817
2010's34 (6.43)24.3611
2020's6 (1.13)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 8.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index8.02 (24.57)
Research Supply Index6.32 (2.92)
Research Growth Index4.34 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (8.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews7 (1.26%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other548 (98.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]